New directions in strategies using cell therapy for heart disease

Journal of Molecular Medicine

Volumn 81, Issue 5, 2003, Pages 288-296

  Itescu, Silviu ^a,b,c   Schuster, Michael D ^b   Kocher, Alfred A ^b  

^a New York Presbyterian Hospital Columbia University Medical Center   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c MONASH UNIVERSITY   (Australia)

Author keywords

Angioblasts therapy; Congestive heart failure; Myocardial infarction; Vascular endothelial cell growth factor; Ventricular remodeling

Indexed keywords

ADOPTIVE IMMUNOTHERAPY; APOPTOSIS; BONE MARROW; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL TRANSPLANTATION; CONGESTIVE HEART FAILURE; HEART DISEASE; HEART MUSCLE CELL; HEART MUSCLE REVASCULARIZATION; HUMAN; IMMUNOGENICITY; NEOVASCULARIZATION (PATHOLOGY); REVIEW; STEM CELL;

EID: 0038458986     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00109-003-0432-0     Document Type: Review

References (76)

1. CONSENSUS (1987) Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS) Trial Study Group. N Engl J Med 316:1429-1435
2. Mahon NG, O'Roke C, Codd MB, et al (1999) Hospital mortality of acute myocardial infarction in the thrombolytic era. Heart 81:478-482
3. Hognes JR (1991) The artificial heart: prototypes, policies and patients. National Academy, Washington
4. United States Department of Health and Human Services (1990) Annual report of the US Scientific Registry for Organ Transplantation and the Organ Procurement and Transplantation Network. US Department of Health and Human Services, Washington
5. Frazier OH, Rose EA, Macmanus Q, et al (1992) Multicenter clinical evaluation of the Heartmate 1000 IP left ventricular assist device. Ann Thorac Surg 102:578-587
6. McCarthy PM, Rose EA, Macmanus Q, et al (1991) Clinical experience with the Novacor ventricular assist system. J Thorac Cardiovasc Surg 102:578-587
7. Oz MC, Argenziano M, Catanese KA, et al (1997) Bridge experience with long-term implantable left ventricular assist devices. Are they an alternative to transplantation? Circulation 95:1844-1852
8. Colucci WS (1997) Molecular and cellular mechanisms of myocardial failure. Am J Cardiol 80:15L-25L
9. Ravichandran LV, Puvanakrishnan R (1991) In vivo labeling studies on the biosynthesis and degradation of collagen in experimental myocardial myocardial infarction. Biochem Int 24:405-414
10. Agocha A, Lee H-W, Eghali-Webb M (1997) Hypoxia regulates basal and induced DNA synthesis and collagen type I production in human cardiac fibroblasts: effects of TGF-beta, thyroid hormone, angiotensis II and basic fibroblast growth factor. J Mol Cell Cardiol 29:2233H-2244H
11. Pfeffer JM, Pfeffer MA, Fletcher PJ, Braunwald E (1991) Progressive ventricular remodeling in rat with myocardial infarction. Am J Physiol 260:H1406-H1414
12. White HD, Norris RM, Brown MA, Brandt PWT, Whitlock RML, Wild CJ (1987) Left ventricular end systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 76:44-51
13. Nelissen-Vrancken H, Debets J, Snoeckx L, Daemen M, Smits J (1996) Time-related normalization of maximal coronary flow in isolated perfused hearts of rats with myocardial infarction. Circulation 93:349-355
14. Kalkman EAJ, Bilgin YM, van Haren P, van Suylen R-J, Saxena PR, Schoemaker RG (1996) Determinants of coronary reserve in rats subjected to coronary artery ligation or aortic banding. Cardiovasc Res 32:1088-1095
15. Heymans S, Luutun A, Nuyens D, et al (1999) Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med 5:1135-1142
16. Hochman JS, Choo H (1987) Limitation of myocardial infarct expansion by reperfusion independent of myocardial salvage. Circulation 75:299-306
17. White HD, Cross DB, Elliot JM, et al (1994) Long-term prognostic importance of patency of the infarct-related coronary artery after thrombolytic therapy for myocardial infarction. Circulation 89:61-67
18. Nidorf SM, Siu SC, Galambos G, Weyman AE, Picard MH (1992) Benefit of late coronary reperfusion on ventricular morphology and function after myocardial infarction. J Am Coll Cardiol 20:307-313
19. MacLellan WR, Schneider MD (2000) Genetic dissection of cardiac growth control pathways Annu Rev Physiol 62:289-320
20. Soonpaa MH, Field LJ (1997) Assessment of cardiomyocyte DNA synthesis in normal and injured adult mouse hearts. Am J Physiol 272:H220-H226
21. Kellerman S, Moore JA, Zierhut W, Zimmer HG, Campbell J, Gerdes AM (1992) Nuclear DNA content and nucleation patterns in rat cardiac myocytes from different models of cardiac hypertrophy. J Mol Cell Cardiol 24:497-505
22. Hill MF, Singal PK (1997) Right and left myocardial antioxidant responses during heart failure subsequent to myocardial infarction. Circulation 96:2414-2240
23. Li Y, Jenkins CW, Nichols MA, Xiong Y (1994) Cell cycle expression and p53 regulation of the cyclin-dependent kinase inhibitor p21. Oncogene 9:2261-2268
24. Steinman RA, Hoffman B, Iro A, Guillouf C, Liebermann DA, El-Houseini ME (1994) Induction of p21 (WAF1/CIP1) during differentiation. Oncogene 9:3389-3396
25. Halevy O, Novitch BG, Spicer DB, Skapek SX, Rhee J, Hannon GJ, Beach D, Lassar AB (1995) Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science 267:1018-1021
26. Andres V, Walsh K (1996) Myogenin expression, cell cycle withdrawal and phenotypic differentiation are temporally separable events that precedes cell fusion upon myogenesis. J Cell Biol 132:657-666
27. Tsurimoto T (1999) PCNA binding proteins. Frontiers Biosci 4:849-858
28. Levkau B, Koyama H, Raines EW, Clurman BE, Herren B, Orth K, Roberts JM, Ross R (2000) Cleavage of p21cip1/waf1 and p27 kip1 mediates apoptosis in endothelial cells through activation of cdk2: role of a caspase cascade. Mol Cell 1:553-563
29. Adachi S, et al (2001) Cyclin A/cdk2 activation is involved in hypoxia-induced apoptosis in cardiomyocytes. Circ Res 88:408
30. Anversa P, Nadal-Ginard B (2002) Myocyte renewal and ventricular remodelling Nature 415:240-243
31. Kajstura J, Leri A, Finato N, di Loreto N, Beltramo CA, Anversa P (1998) Myocyte proliferation in end-stage cardiac failure in humans. Proc Natl Acad Sci USA 95:8801-8805
32. Beltrami AP, et al (2001) Evidence that human cardiac myocytes divide after myocardial infarction. N Engl J Med 344:1750-1757
33. Makino S, Fukuda K, Miyoshi S, et al (1999) Cardiomyocytes can be generated from marrow stromal cells in vitro. J Clin Invest 103:697-705
34. Tomita S, Li R-K, Weisel RD, et al (1999) Autologous transplantation of bone marrow cells improves damaged heart function. Circulation 100:II-247
35. Pittenger MF, Mackay AM, Beck SC, et al (1999) Multilineage potential of adult human mesenchymal stem cells. Science 284:143-147
36. Liechty KW, MacKenzie TC, Shaaban AF, et al (2000) Human mesenchymal stem cells engraft and demonstrate site-specific differentiation after in utero transplantation in sheep. Nat Med 6:1282-1286
37. Kehat I, Kenyagin-Karsenti D, Snir M, Segev H, Amit M, Gepstein A, Livne E, Binah O, Itskovitz-Eldor J, Gepstein L (2001) Human embryonic stem cells can differentiate into myocytes with structural and functional properties of cardiomyocytes. J Clin Invest 108:407-414
38. Klug MG, Soonpaa MH, Koh GY, Field LJ (1996) Genetically selected cardiomyocytes from differentiating embryonic stem cells form stable intracardiac grafts. J Clin Invest 98:216-224
39. Hescheler J, Fleischmann BK, Wartenberg M, Bloch W, Kolossov E, Ji G, Addicks K, Sauer H (1999) Establishment of ionic channels and signalling cascades in the embryonic stem cell-derived primitive endoderm and cardiovascular system. Cells Tissues Organs 165:153-164
40. Taylor DA, Atkins BZ, Hungspreugs P, Jones TR, Reedy MC, Hutcheson KA, Glower DD, Kraus WE (1998) Regenerating functional myocardium: improved performance after skeletal myoblast transplantation. Nat Med 4:929-933
41. Field L (1999) Future therapy for cardiovascular disease. In: Proceedings of the NHLBI Workshop Cell Transplantation: future therapy for cardiovascular disease? Columbia
42. Murry CE, Wiseman RW, Schwartz SM, Hauschka SD (1996) Skeletal myoblast transplantation for repair of myocardial necrosis. J Clin Invest 98:2512-2523
43. Atkins BZ, Hueman MT, Meuchel JM, Cottman MJ, Hutcheson KA, Taylor DA (1999) Myogenic cell transplantation improves in vivo regional performance in infarcted rabbit myocardium. J Heart Lung Transpl 18:1173-1180
44. Suzuki K, Smolenski RT, Jayakumar J, Murtuza B, Brand NJ, Yacoub MH (2000) Heat shock treatment enhances graft cell survival in skeletal myoblast transplantation to the heart. Circulation 102:III216-III221
45. Pouzet B, Ghostine S, Vilquin J-T, Garcin I, Scorsin M, Hagege AA, Duboc D, Schwartz K, Menasche P (2001) Is skeletal myoblast transplantation clinically relevant in the era of angiotensin-converting enzyme inhibitors? Circulation 104: I223-1228
46. Menasche P, Hagege AA, Scorsin M, Pouzet B, Desnos M, Duboc D, Schwartz K, Vilquin J-T, Marolleau J-P (2001) Myoblast transplantation for heart failure. Lancet 347:279
47. Beauchamp JR, Morgan JE, Pagel CN, Partridge TA (1999) Dynamics of myoblast transplantation reveal a discrete minority of precursors with stem cell-like properties as the myogenic source. J Cell Biol 144:1113-1122
48. Smythe GM, Grounds MD (2000) Exposure to tissue culture conditions can adversely affect myoblast behaviour in vivo in whole muscle grafts: implications for myoblast transfer therapy. Cell Transplant 9:379-393
49. Smythe GM, Hodgetts SI, Grounds MD (2001) Problems and solutions in myoblast transfer therapy. J Cell Mol Med 5:33-47
50. Hodgetts SI, Beilharz MW, Scalzo T, Grounds MD (2000) Why do cultured transplanted myoblasts die in vivo? DNA quantification shows enhanced survival of donor male myoblasts in host mice depleted of CD4+ and CD8+ or NK1.1+ cells. Cell Transplant 9:489-502
51. Maier S, Tertilt C, Chambron N, Gerauer K, Huser N, Heidecke C-D, Pfeffer K (2001) Inhibition of natural killer cells results in acceptance of cardiac allografts in CD28-/mice. Nat Med 7:557-562
52. Zhang M, Methot D, Poppa V, Fujio Y, Walsh K, Murry CE (2001) Cardiomyocyte grafting for cardiac repair: graft cell death and anti-death strategies. J Mol Cell Cardiol 33:907-921
53. Jackson KA, Majka SM, Wang H, Pocius J, Hartley CJ, Majesky MW, Entman ML, Michael LH, Hirschi KK, Goodell MA (2001) Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cells. J Clin Invest 107:1395-1402
54. Orlic D, Kajstura J, Chimenti S, et al (2001) Bone marrow cells regenerate infarcted myocardium. Nature:410:701-705
55. Tavian M, Coulombel L, Luton D, San Clemente H, Dieterlen-Lievre F, Peault B (1996) Aorta-associated CD34 hematopoietic cells in the early human embryo. Blood 87:67-72
56. Jaffredo T, Gautier R, Eichmann A, Dieterlen-Lievre F (1998) Intraaortic hemopoietic cells are derived from endothelial cells during ontogeny. Development 125:4575-4583
57. Kennedy M, Firpo M, Choi K, Wall C, Robertson S, Kabrun N, Keller G (1997) A common precursor for primitive erythropoiesis and definitive haematopoiesis. Nature 386:488-493
58. Choi K, Kennedy M, Kazarov A, Papadimitriou, Keller G (1998) A common precursor for hematopoietic and endothelial cells. Development 125:725-732
59. Elefanty AG, Robb L, Birner R, Begley CG (1997) Hematopoietic-specific genes are not induced during in vitro differentiation of scl-null embryonic stem cells. Blood 90:1435-1447
60. Labastie M-C, Cortes F, Romeo P-H, Dulac C, Peault B (1998) Molecular identity of hematopoietic precursor cells emerging in the human embryo. Blood 92:3624-3635
61. Tsai FY, Keller G, Kuo FC, Weiss M, Chen J, Rosenblatt M, Alt FA, Orkin SH (1994) An early hematopoietic defect in mice lacking the transcription factor GATA-2. Nature 371:221-225
62. Ogawa M, Kizumoto M, Nishikawa S, Fujimoto T, Kodama H, Nishikawa SI (1999) Blood 93:1168-1177
63. Asahara T, et al (1997) Isolation of putative progenitor cells for endothelial angiogenesis. Science 275:964-967
64. Folkman J (1998) Therapeutic angiogenesis in ischemic limbs. Circulation 97:108-110
65. Takahashi T, et al (1999) Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med 5:434-438
66. Kalka C, et al (2000) Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc Natl Acad Sci USA 97:3422-3427
67. Rafii S, Shapiro F, Rimarachin J, Nachman R, Ferris B, Weksler B, Moore AS, Asch AS (1994) Isolation and characterization of human bone marrow microvascular endothelial cells: hematopoietic progenitor cell adhesion. Blood 84:10-19
68. Shi Q, Rafii S, Wu MH-D, et al (1998) Evidence for circulating bone marrow-derived endothelial cells. Blood 92:362-367
69. Lin Y, Weisdorf DJ, Solovey A, Hebbel RP (2000) Origins of circulating endothelial cells and endothelial outgrowth from blood. J Clin Invest 105:71-77
70. Kocher AA, Schuster MD, Szabolcs MJ, Takuma S, Burkhoff D, Wang J, Homma S, Edwards NM, Itescu S (2001) Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med 7:430-436
71. Asahara T, Takahashi T, Masuda H, Kalka C, Chen D, Iwaguro H, Inai Y, Silver M, Isner JM (1999) VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J 18:3964-3972
72. Kocher A, Schuster M, Szabolcs M, Itescu S (2003) Cardiomyocyte regeneration after neovascularization of ischemic myocardium by human bone marrow-derived angioblasts. Nat Med (in press)
73. McEwan PE, Gray GA, Sherry L, Webb DJ, Kenyon CJ (1998) Differential effects of angiotensin II on cardiac cell proliferation and intramyocardial perivascular fibrosis in vivo. Circulation 98:2765-2773
74. Kawano H, Do YS, Kawano Y, Starnes V, Barr M, Law RE, Hsueh WA (2000) Angiotensin II has multiple profibrotic effects in human cardiac fibroblasts. Circulation 101:1130-1137
75. Pfeffer MA, Braunwald E, Moye LA, et al (1992) Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE investigators. N Engl J Med 327:669-677
76. Pitt B, Segal R, Martinez FA, et al (1997) Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 349:747-752